Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October

By Cory Renauer – Nov 10, 2018 at 7:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Following the acquisition of a start-up biotech, Sangamo saw its stock tumble along with the rest of its industry.

What happened

Shares of Sangamo Therapeutics Inc. (SGMO -3.43%), a pre-commercial biotechnology company developing gene therapies, fell 25.3% in October, according to data from S&P Global Market Intelligence. After completing the acquisition of a French start-up to begin the month, the stock followed the rest of its industry lower.

So what 

The month of October was a rough one across the board. The Nasdaq Biotechnology Index fell 13.9%, and companies like Sangamo that don't have any approved drugs to sell fell harder than those with reliable revenue streams.

Frustrated trader yelling at his computer screen.

Image source: Getty Images.

Sangamo investors were less than thrilled with the $82 million acquisition of TxCell, a French biotech developing regulatory T cells. The acquired company won't be ready to submit its first clinical-trial authorization application until next year, but Sangamo insists the acquisition will accelerate its entry into the market for cellular cancer therapies.

Now what

At the moment, just two cellular cancer therapies are generating significant sales, and their first several quarters haven't been remarkable. A report last month in Nature Reviews Drug Discovery found 412 experimental cellular cancer therapies in clinical-stage development, which means there could be a lot more potential competition by the time Sangamo has one of its own in human testing.

While Sangamo's oncology pipeline probably isn't going anywhere fast, investors can look forward to results from the Alta study with SB-525, a hemophilia candidate partnered with Pfizer (PFE -0.57%). In October, a safety monitoring committee said it's safe enough to try a higher dosage, and Sangamo will present efficacy data from the study once dose escalation is complete.

So far in November, Sangamo has fallen another 20.1%

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
SGMO
$4.78 (-3.43%) $0.17
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.83 (-0.57%) $0.25
Nasdaq, Inc. Stock Quote
Nasdaq, Inc.
NDAQ
$56.57 (-0.63%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.